Life Sciences Tools and Services
Company Overview of CyDex Pharmaceuticals, Inc.
CyDex Pharmaceuticals, Inc. develops and licenses Captisol, a drug formulation technology that enables new product development by improving the solubility, stability, bioavailability, and dosing of active pharmaceutical ingredients (APIs). Its Captisol drug formulation technology is designed to maximize safety by eliminating the damaging effects produced by the parent beta-cyclodextrin; and enable an aqueous formulation for various water insoluble APIs as oral, nasal, topical, ophthalmic, or liquid-presented medications. The company also has license and supply agreements in place with various pharmaceutical companies worldwide with Captisol-enabled product candidates. In addition, it offers ...
10513 West 84th Terrace
Lenexa, KS 66214
Founded in 1993
Key Executives for CyDex Pharmaceuticals, Inc.
Senior Director of Business Development and Investor Relations
Vice President of Business Development & Marketing
Director of Corporate Development
Compensation as of Fiscal Year 2015.
CyDex Pharmaceuticals, Inc. Key Developments
Marinus Pharmaceuticals Seals Deal with CyDex Pharmaceuticals, Inc. for Clinical Use of Captisol
Aug 12 14
Marinus Pharmaceuticals signed an agreement with CyDex Pharmaceuticals for the clinical use of Captisol. Captisol is a uniquely modified cyclodextrin, whose chemical structure was designed to improve solubility, stability, bioavailability and dosing of active pharmaceutical ingredients. MRNS said it plans to use Captisol to evaluate ways to optimize its intravenous dose form of ganaxolone.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries